Inhibitory activities and possible anticancer targets of Ru(II)-based complexes using computational docking method

Journal of Molecular Graphics and Modelling

Volumn 38, Issue , 2012, Pages 60-69

  Adeniyi, Adebayo A ^a   Ajibade, Peter A ^a  

^a UNIVERSITY OF FORT HARE   (South Africa)

Author keywords

Cancer receptors; Carboxylic; Docking; Ru(II) based complexes; Selectivity

Indexed keywords

ANTI-CANCER AGENTS; ANTIBACTERIAL AGENT; ANTICANCER TARGETS; CANCER RECEPTORS; CARBOXYLIC; CIS-PLATIN; COMPUTATIONAL DOCKINGS; CYTOTOXIC; INHIBITORY ACTIVITY; PHARMACOKINETIC PROPERTIES; PROTEIN TARGETS; RESEARCH CHALLENGES;

CATALYST SELECTIVITY; DNA; DOCKING;

RUTHENIUM ALLOYS;

DNA TOPOISOMERASE (ATP HYDROLYSING); PHOSPHOTRANSFERASE; RUTHENIUM COMPLEX;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL INTERACTION; COMPUTER ANALYSIS; DRUG PROTEIN BINDING; DRUG TARGETING; MOLECULAR DOCKING; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BINDING SITES; COORDINATION COMPLEXES; DNA GYRASE; DRUG DESIGN; HISTONE DEACETYLASES; HUMANS; LIGANDS; MOLECULAR DOCKING SIMULATION; NEOPLASM PROTEINS; ORPHAN NUCLEAR RECEPTORS; RUTHENIUM;

EID: 84867429632     PISSN: 10933263     EISSN: 18734243     Source Type: Journal    
DOI: 10.1016/j.jmgm.2012.08.004     Document Type: Article

References (39)

1. M. Groessl, Y.O. Tsybin, C.G. Hartinger, B.K. Keppler, and P.J. Dyson Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry Journal of Biological Inorganic Chemistry 15 2009 677 688
2. S. Chatterjee, S. Kundu, A. Bhattacharyya, C.G. Hartinger, and P.J. Dyson The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways Journal of Biological Inorganic Chemistry 13 2008 1149 1155
3. 2]: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand Journal of Biological Inorganic Chemistry 15 2010 919 927
4. 2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo- [3.3.1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells Chemical Communications 2001 1396 1397
5. P.J. Dyson, and G. Sava Metal-based antitumour drugs in the post genomic era Dalton Transactions 23 2006 1929 1933
6. G. Sava, A. Bergamoa, and P.J. Dyson Metal-based antitumour drugs in the post-genomic era: what comes next? Dalton Transactions 40 2011 9069 9075
7. C.S. Allardyce, A. Dorcier, C. Scolaro, and P.J. Dyson Development of organometallic (organo-transition metal) pharmaceuticals Advances in Organometallic Chemistry 19 2005 1 10
8. 2(pta)] (pta = 1,3,5-triaza-7-phosphatricyclo-[3.3. 1.1]decane): a water soluble compound that exhibits pH dependent DNA binding providing selectivity for diseased cells Chemical Communications 2001 1396 1397
9. B. Dutta, C. Scolaro, R. Scopelliti, P.J. Dyson, and K. Severin Importance of the π-ligand: remarkable effect of the cyclopentadienyl ring on the cytotoxicity of ruthenium pta compounds Organometallics 27 2008 1355 1357
10. W. Hu, Q. Luo, X. Ma, K. Wu, J. Liu, Y. Chen, S. Xiong, J. Wang, P.J. Sadler, and F. Wang Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes Chemistry: A European Journal 15 2009 6586 6594
11. F. Wang, A. Habtemariam, E.P.L. van der Geer, R. Fernandez, M. Melchart, R.J. Deeth, R. Aird, S. Guichard, F.P.A. Fabbiani, P. Lozano-Casal, I.D.H. Oswald, D.I. Jodrell, S. Parsons, and P.J. Sadler Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity Proceedings of the National Academy of Sciences of the United States of America 102 2005 18269 18274
12. M. Hanif, H. Henke, S.M. Meier, S. Martic, M. Labib, W. Kandioller, M.A. Jakupec, V.B. Arion, H. Kraatz, B.K. Keppler, and C.G. Hartinger Is the reactivity of M(II)-arene complexes of 3-hydroxy-2(1H)-pyridones to biomolecules the anticancer activity determining parameter? Inorganic Chemistry 49 2010 7953 7963
13. G. Gasser, I. Ott, and N. Metzler-Nolte Organometallic anticancer compounds Journal of Medicinal Chemistry 54 2011 3 25
14. A. Casini, C. Gabbiani, F. Sorrentino, M.P. Rigobello, A. Bindoli, T.J. Geldbach, A. Marrone, N. Re, C.G. Hartinger, P.J. Dyson, and L. Messori Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds Journal of Medicinal Chemistry 51 2008 6773 6781
15. S. Page Ruthenium compounds as anticancer agents Education in Chemistry 2012 26 29 www.rsc.org/eic
16. C.S. Allardyce, and P.J. Dyson Ruthenium in medicine: current clinical uses and future prospects Platinum Metal 45 2 2001 62 69
17. Research Collaboratory for Structural Bioinformatics (RCSB) (2012), Online pdb database: www.rcsb.org.
18. Y.N.V. Gopal, D. Jayaraju, and A.K. Kondapi Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action Biochemistry 38 1999 4382 4388
19. G. Arpino, D.R. Ciocca, H. Weiss, D.C. Allred, P. Daguerre, L. Vargas-Roig, M. Leuzzi, F. Gago, R. Elledge, and S.K. Mohsin Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIa for anthracycline chemotherapy in locally advanced breast cancer Breast Cancer Research and Treatment 92 2005 69 75
20. C.J. World, H. Yamawaki, and B.C. Berk Thioredoxin in the cardiovascular system Journal of Molecular Medicine 84 2006 997 1003
21. C. Cadenas, D. Franckenstein, M. Schmidt, M. Gehrmann, M. Hermes, B. Geppert, W. Schormann, L.J. Maccoux, M. Schug, A. Schumann, C. Wilhelm, E. Freis, K. Ickstadt, J. Rahnenführer, J.I. Baumbach, A. Sickmann, and J.G. Hengstler Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer Breast Cancer Research 12 2010 R44
22. P. Xie, C. Streu, J. Qin, H. Bregman, N. Pagano, E. Meggers, and R. Marmorstein The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase Biochemistry 48 2009 5187 5198
23. B. Wu, M.S. Ong, M. Groessl, Z. Adhireksan, C.G. Hartinger, P.J. Dyson, and C.A. Davey A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core Chemistry: A European Journal 17 2011 3562 3566
24. G.A. Holdgate, A. Tunnicliffe, W.H.J. Ward, S.A. Weston, G. Rosenbrock, P.T. Barth, I.W.F. Taylor, R.A. Pauptit, and D. Timms The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: a thermodynamic and crystallographic study Biochemistry 36 1997 9663 9673
25. S. Ghaneya, G.S. Hassan, A. Nahla, N.A. Farag, H. Gehan, G.H. Hegazy, K. Reem, and R.K. Arafa Design and synthesis of novel benzopyran-2-one derivatives of expected antimicrobial activity through DNA gyrase-B inhibition Archiv der Pharmazie: Chemistry in Life Sciences 341 2008 725 733
26. X. Hu, and W.H. Shelver Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction Journal of Molecular Graphics and Modelling 22 2003 115 126
27. A.A. Granovsky Firefly, Version 7.1.G, Copyright 1994 2009 Firefly Project Moscow, Russia http://classic.chem.msu.su/gran/firefly/index.html
28. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, and A.J. Olson Autodock4 andAutoDockTools4: automated docking with selective receptor flexibility Journal of Computational Chemistry 30 16 2009 2785 2791
29. R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, D.E. Shaw, M. Shelley, J.K. Perry, P. Francis, and P.S. Shenkin Glide: new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy Journal of Medicinal Chemistry 47 2004 1739 1749
30. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin UCSF Chimera - a visualization system for exploratory research and analysis Journal of Computational Chemistry 25 13 2004 1605 1612
31. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function Journal of Computational Chemistry 19 14 1998 1639 1662
32. + channel Journal of Molecular Modeling 13 2007 579 586
33. T.A. Halgren, R.B. Murphy, R.A. Friesner, H.S. Beard, L.L. Frye, W.T. Pollard, and J.L. Banks Glide: new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening Journal of Medicinal Chemistry 47 2004 1750 1759
34. C.R. Corbeil, and N. Moitessier Docking ligands into flexible and solvated macromolecules. 3. Impact of input ligand conformation, protein flexibility, and water molecules on the accuracy of docking programs Journal of Chemical Information and Modeling 49 2009 997 1009
35. M.P. Jacobson, D.L. Pincus, C.S. Rapp, T.J.F. Day, B. Honig, D.E. Shaw, and R.A. Friesner A hierarchical approach to all-atom protein loop prediction Proteins 55 2004 351 367
36. P. Heffeter, K. Bock, B. Atil, M.A.R. Hoda, W. Korner, C. Bartel, U. Jungwirth, B.K. Keppler, M. Micksche, W. Berger, and G. Koellensperger Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339 Journal of Biological Inorganic Chemistry 15 2010 737 748
37. C.G. Hartinger, M.A. Jakupec, S. Zorbas-Seifried, M. Groessl, A. Egger, W. Berger, H. Zorbas, P.J. Dyson, and B.K. Keppler KP1019: a new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients Chemistry & Biodiversity 5 2008 2140 2155
38. W.H. Ang, E. Daldini, C. Scolaro, R. Scopelliti, L. Juillerat-Jeannerat, and P.J. Dyson Development of organometallic ruthenium-arene anticancer drugs that resist hydrolysis Inorganic Chemistry 45 2006 9006 9013
39. D.-L. Ma, V.P.-Y. Ma, D.S.-H. Chan, K.-H. Leung, H.-J. Zhong, and C.-H. Leung In silico screening of quadruplex-binding ligands Methods 57 2012 106 114